Elanix Biotechnologies AG Announces Non-Binding Letter of Intent with Oxford MEstar Ltd. in Regard to Setting up a JV to Market GynRepair in China

POTSDAM, Germany–(BUSINESS WIRE)–Elanix Biotechnologies AG today announced that the company has entered
into a non-binding letter of intent (LOI) with Oxford MEStar Ltd
(“MEStar”), an Oxford University spin-out. The LOI contains broad terms
of a potential transaction whereby the two companies, together with
Tianjin-based UniNova, might establish a Chinese JV. In the first
instance this would market Elanix’s GynRepair, used for the treatment of
vulvodynia, in the domestic market in China (PRC). The transaction is
necessarily subject to entering into a definitive agreement between the
parties, containing specific signing and closing terms and conditions
yet to be finalised, negotiated and agreed up.

Professor Zhanfeng Cui, the founder of MEStar, commented: “We look
forward to collaborating with Elanix, whose tissue repair products we
believe have significant commercial potential”.

Tomas Svoboda, CEO of Elanix Biotechnologies AG, added: “We are very
pleased to find such reputable partners that will accelerate our
territorial expansion for our innovative bioactive creams”.

Tomas Svoboda, CEO

About MEStar

Oxford MEStar Limited is a spin-out company from the Institute of
Biomedical Engineering of Oxford University specializing in
translational and regenerative medicine and healthcare. The company is
focused on a) developing novel technologies; b) offering bioengineering
solutions to clients; and c) technology transfer between Europe and
China.

For more information, please contact Dr Zoe Li on 01865 784436 or visit www.oxford-mestar.com

About UniNova

UniNova is the Oxford MEStar sister company, incorporated in Nov 2014
with 80 million RMB private investment and with the support of Tianjin
Municipal Government. UniNova’s goal is to provide a one-stop solution
for SMEs in biotechnology, biomedical and healthcare, so they can land
in China smoothly and access the Chinese market in a timely manner.

About Elanix

Elanix Biotechnologies AG (Frankfurt SX: ELN) develops and
commercializes tissue regeneration products for acute wound care,
dermatological and gynaecological applications, and provides services in
cell technologies. The company was founded in 2013 as a spin-out from
the University Hospital of Lausanne (CHUV), Switzerland, to
commercialize a patented progenitor cell technology. Progenitor cells
are fully differentiated yet immunologically neutral cells that are very
potent inducers of tissue growth and healing. Elanix owns GMP certified
Master and Working cell banks with vast quantities of cells of different
cell types.

The Company is headquartered in Nyon, Switzerland with offices in
Potsdam and listed on the Frankfurt stock exchange under the symbol ELN.
For more information and updates, visit www.elanix-biotechnologies.com.

Disclaimer / Forward-looking statements:

This communication does not constitute an offer or invitation to
subscribe for or purchase any securities of Elanix Biotechnologies AG.
This announcement does not contain or constitute an offer of, or the
solicitation of an offer to buy or subscribe for, securities to any
person in the United States of America (the “United States”), Australia,
Canada or Japan or in any jurisdiction to whom or in which such offer or
solicitation is unlawful. The securities referred to in this
announcement will not be and have not been registered under the U.S.
Securities Act of 1933, as amended (the “U.S. Securities Act”) and may
not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements under the U.S.
Securities Act. Subject to certain exceptions, the securities referred
to in this announcement may not be offered or sold in Australia, Canada
or Japan, or to, or for the account or benefit of, any national,
resident or citizen of Australia, Canada or Japan. The offer and sale of
the securities referred to in this announcement has not been and will
not be registered under the U.S. Securities Act or under the applicable
securities laws of Australia, Canada or Japan. There will be no public
offer of the securities in the United States.

This publication may contain certain forward-looking statements
concerning the Company and its business. Such statements involve certain
risks, uncertainties and other factors which could cause the actual
results, financial condition, performance or achievements of the Company
to be materially different from those expressed or implied by such
statements. Readers should therefore not place undue reliance on these
statements, particularly not in connection with any contract or
investment decision. The Company disclaims any obligation to update
these forward-looking statements.

Language:		English
Company:		Elanix Biotechnologies AG
		Domstr. 22
		14482 Potsdam
		Germany
ISIN:		DE000A0WMJQ4
WKN:		A0WMJQ
Listed:		Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf

Contacts

Elanix Biotechnologies AG
Maria Widowski
E-mail: investor.relations@elanix-bt.com
Phone
number: +49 331 583 945 10